Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Trial on tap in Transcend Medical’s patent spat with Glaukos
A federal judge said a jury will decide whether Glaukos tried to hide the role of 1 of the inventors if its eye stent in patent filings, in a lawsuit with rival Transcend Medical.
In 3 decisions issued Sept. 18, Judge Mitchell Goldberg of the U.S. District Court for Delaware ruled that Transcend’s CyPass device does not infringe the Glaukos patents, granted in part and denied in part another Transcend motion for summary judgment on invalidity, and scheduled a trial for Nov. 2 over Transcend’s inequitable conduct claim that Glaukos deliberately tried to obscure the role of a professor of ophthalmology at the University of California, Irvine in creating its iStent device. Read more
2. Plaintiff with murder conviction drops pelvic mesh lawsuit against Boston Scientific
The plaintiff in a pelvic mesh lawsuit, who wanted evidence of her murder conviction kept out of her case against Boston Scientific, dropped the suit last week.
Ramona Winebarger, who in 1995 pleaded guilty to murder in the death of her 1st husband and the shooting of another man, withdrew her suit Sept. 17, according to court documents. Winebarger served 8 years of a 35-year sentence. Earlier this month she lost a bid to quash a Boston Scientific subpoena seeking her employment records, according to court filings. Read more
1. NovoCure sets terms on $206m IPO
NovoCure set the terms on its forthcoming initial public offering, saying it expects to float 7.5 million shares at $26 to $29 apiece, or $206.3 million at the midpoint of the range.
NovoCure said it expects to net about $189 million from the offering, which includes an underwriters allotment for another nearly 1.9 million shares. Read more